Starpharmaの企業価値
Starpharmaの企業価値は何ですか。
Starpharma Holdings Limitedの企業価値は114.27M$です。
企業価値の定義は何ですか。
企業価値は、企業の総市場価値の尺度です。これは、負債、少数株主持分および優先株式から現金および現金同等物を差し引いた時価総額として計算されます。
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
ASXのセクタHealth Careにおける企業価値の企業と比べるStarpharma
Starpharmaは何をしますか。
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharmaと類似の企業価値
- Pure Gold Miningの企業価値は113.91M$です。
- Suoxindaの企業価値は114.05M$です。
- Amaroq Minerals Ltdの企業価値は114.10M$です。
- Dixieの企業価値は114.16M$です。
- smartphoto group NVの企業価値は114.18M$です。
- Ramco Systemsの企業価値は114.25M$です。
- Starpharmaの企業価値は114.27M$です。
- Alpha Real Trustの企業価値は114.32M$です。
- Sylogistの企業価値は114.35M$です。
- ScS Plcの企業価値は114.38M$です。
- Paragon ID SAの企業価値は114.38M$です。
- Probe Metalsの企業価値は114.42M$です。
- Zoetic International Plcの企業価値は114.43M$です。